Aytu Biopharma, Inc.
AYTU
$2.13
-$0.05-2.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.17M | 13.89M | 15.14M | 18.45M | 16.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.17M | 13.89M | 15.14M | 18.45M | 16.22M |
| Cost of Revenue | 5.54M | 4.70M | 4.88M | 5.65M | 5.44M |
| Gross Profit | 9.62M | 9.19M | 10.25M | 12.81M | 10.79M |
| SG&A Expenses | 11.07M | 10.25M | 8.48M | 9.30M | 9.72M |
| Depreciation & Amortization | 526.00K | 444.00K | 921.00K | 920.00K | 921.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.14M | 15.39M | 14.50M | 16.03M | 16.60M |
| Operating Income | -1.97M | -1.50M | 640.00K | 2.42M | -378.00K |
| Income Before Tax | -10.58M | 1.97M | -19.44M | 3.82M | 382.00K |
| Income Tax Expenses | -- | -- | 437.00K | -122.00K | -283.00K |
| Earnings from Continuing Operations | -10.58M | 1.97M | -19.88M | 3.94M | 665.00K |
| Earnings from Discontinued Operations | -- | -- | 62.00K | 54.00K | 123.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.58M | 1.97M | -19.82M | 3.99M | 788.00K |
| EBIT | -1.97M | -1.50M | 640.00K | 2.42M | -378.00K |
| EBITDA | -1.09M | -701.00K | 1.93M | 3.74M | 914.00K |
| EPS Basic | -1.05 | 0.21 | -2.92 | 0.65 | 0.13 |
| Normalized Basic EPS | -0.66 | 0.13 | -1.03 | 0.39 | 0.17 |
| EPS Diluted | -1.05 | -0.08 | -2.92 | 0.21 | -0.26 |
| Normalized Diluted EPS | -0.66 | 0.06 | -1.03 | 0.29 | 0.13 |
| Average Basic Shares Outstanding | 10.04M | 9.44M | 6.79M | 6.13M | 6.13M |
| Average Diluted Shares Outstanding | 10.04M | 19.48M | 6.79M | 8.20M | 8.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |